During a recent event in New York, Pfizer Chief Executive Albert Bourla underscored the necessity of collaboration between the U.S. and Chinese pharmaceutical industries. He noted that China's swift processes have elevated its role in global drug development, accounting for 30% of the sector over the last decade.

Bourla was speaking at the National Committee on U.S.-China Relations Gala, pointing out that China now boasts approximately 1,200 novel drug candidates, compared to just 60 a decade ago. Despite the U.S.-China trade war, pharmaceutical collaborations continue to flourish.

For instance, Pfizer recently entered into an agreement with China's 3SBio Inc, investing $1.25 billion in an experimental cancer treatment. Bourla highlighted that Chinese biotech companies were responsible f

See Full Page